Farnoush Abar
Hematology & Oncology · Seattle, WANPI 1558560342
Payments from drug & device makers
Across 85 payments — averaging $2115.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$160K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Johnson & Johnson$307
- Amgen$48
- Novartis$44
- Genentech USA, Inc.$34
- plus $270 from 14 others
What the payments were for
- Speaking & faculty fees$15,95080%
- Travel & lodging$2,76414%
- Food & beverage$1,1276%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 33 | $159,933 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $19,188 |
| Johnson & Johnson | 14 | $307 |
| Amgen | 2 | $48 |
| Novartis | 2 | $44 |
| Genentech USA, Inc. | 2 | $34 |
| Merck | 2 | $32 |
| Seagen Inc. | 2 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| AbbVie | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$18,937
How this compares
$179,825 in reported general payments places this provider in the 70th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $274,237 |
| BrukinsaZanubrutinib | 15 | $218,183 |
| VerzenioAbemaciclib | 14 | $213,860 |
| EliquisApixaban | 36 | $30,943 |
| Abiraterone Acetate | 22 | $20,324 |
| Imatinib Mesylate | 23 | $12,548 |
| Acyclovir | 47 | $615 |
| Letrozole | 36 | $501 |
| Oxycodone Hcl | 35 | $474 |
| Tamoxifen Citrate | 23 | $450 |
| Olanzapine | 18 | $406 |
| Dexamethasone | 31 | $343 |
| Hydroxyurea | 18 | $328 |
| Prednisone | 45 | $304 |
| Anastrozole | 11 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $17 | $214,26632 claims |
| PfizerEliquis | $21 | $30,94336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.